Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hydrogen-generating silicon-based agent is effective in a mouse model of ovalbumin-induced allergic bronchial asthma.

Biomedical journal·2026
Same author

Trisomy 8 clonal expansion during disease progression and azacitidine resistance in VEXAS syndrome: a case report.

Frontiers in immunology·2026
Same author

Graded surgical stress reveals postoperative behavioral changes associated with systemic oxidative stress.

Scientific reports·2026
Same author

Relative HU profiling on clinical CT estimates the subchondral bone plate boundary: an ex vivo cadaveric mechanical validation study.

Scientific reports·2026
Same author

Region-specific cortico-striatal transcriptomic remodeling following early postnatal dopaminergic disturbance.

bioRxiv : the preprint server for biology·2026
Same author

Treatment of cisplatin-induced olfactory aversion based on selection logic: A novel approach.

Behavioral neuroscience·2026

Related Experiment Video

Updated: Mar 28, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.1K

Silicon-based agent mitigates fatty liver formation in a CDAHFD60-induced MASH mouse model by enhancing hepatic

Yoshihisa Koyama1,2, Yuki Kobayashi3, Ikuei Hirota1

  • 1Department of Neuroscience and Cell Biology, Graduate School of Medicine, The University of Osaka, Osaka, 565-0871, Japan.

Biochemistry and Biophysics Reports
|March 27, 2026
PubMed
Summary

Silicon (Si)-based agents show promise for treating metabolic dysfunction-associated steatohepatitis (MASH). This antioxidant therapy improved liver health and systemic metabolism in a MASH mouse model.

Keywords:
CDAHFD60Fatty liverMASHMetabolic dysfunction-associated steatohepatitisSi-based agent

More Related Videos

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.5K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.2K

Related Experiment Videos

Last Updated: Mar 28, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.1K
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.5K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.2K

Area of Science:

  • Hepatology
  • Metabolic Disorders
  • Oxidative Stress Research

Background:

  • Metabolic dysfunction-associated steatohepatitis (MASH) is a growing liver disease linked to obesity and metabolic syndrome.
  • MASH progression increases risks for cardiovascular events, cirrhosis, and liver cancer.
  • Oxidative stress is a key driver of MASH, necessitating antioxidant-based therapies.

Purpose of the Study:

  • To investigate the therapeutic potential of a silicon (Si)-based agent in a mouse model of MASH.
  • To evaluate the effects of Si-based agent on hepatic lipid accumulation, bile dysfunction, and systemic metabolism.

Main Methods:

  • A choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD60) was used to induce MASH in mice.
  • Mice were administered a Si-based agent mixed into their diet for 12 weeks.
  • Hepatic lipid accumulation, bile dysfunction, weight changes, and systemic oxidative stress were assessed.

Main Results:

  • Si-based agent treatment reduced hepatic lipid droplet accumulation by mitigating bile dysfunction.
  • Treatment alleviated hypolipidemia and suppressed weight loss observed in the MASH model.
  • The Si-based agent demonstrated systemic antioxidant effects, reducing overall oxidative stress.

Conclusions:

  • Silicon (Si)-based agents show therapeutic potential for MASH by improving hepatic and systemic lipid metabolism.
  • The antioxidant properties of Si-based agents contribute to their beneficial effects in MASH.
  • Further research into Si-based agents could lead to novel treatments for MASH and related metabolic disorders.